Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC01 in Early Acute HIV Infection
NCT02591420Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2016
- Primary completion
- Mar 2021
- Modality
- Anti-infectious Disease mAbs
- Countries
- 4
01
Overview
Phase 1, randomised trial of VRC01 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Grade 3 or Greater mAb-related Reactogenicity and mAb-related Adverse Events at 24 weeks and Plasma Viral Load Change From Day 0 to Day 7. Started Apr 2016; status: completed.
02
Drugs
VRC01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02591420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591420.